Patient Assessment of Bowel Function During and After Pelvic Radiotherapy: Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial Consecutive patients were ...
Overall Study Population Achieved ORR of 70.8% and DCR of 100.0%; Responses Consistent Across Ivonescimab Dose Levels Combined with Chemotherapy Acceptable and Manageable Safety Profile for ...
On Saturday, Johnson & Johnson (NYSE: JNJ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study. The trial is evaluating Rybrevant (amivantamab-vmjw) in combination with FOLFOX or ...
Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in KRAS G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreaK 300.
Over the past decade, first-line treatment with PD-1 or PD-L1 blockade combined with standard chemotherapy regimen as a combination of a platinum drug (cisplatin or oxaliplatin) and a fluoropyrimidine ...
Pivotal Phase 3 studies, including the global, randomized OrigAMI-2 and OrigAMI-3 studies evaluating subcutaneous amivantamab with FOLFOX and FOLFIRI, are underway to further evaluate the potential of ...
Practice guidelines recommend panitumumab with chemotherapy to treat KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. However, not all patients respond to this therapy. We propose a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results